iOmx Therapeutics AG

2 trials Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

1 Completed trials

3 Countries active

3 Unique IMPs

100% Results reported

Phase I

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

IOMX-0675 1 OMX-0407 1 PEMBROLIZUMAB 1

All trials

2 total

A study to test the safety and effects of IOMX-0675, an antibody treatment, alone or with pembrolizumab, in patients with advanced or spread… Pending

2024-517449-14-00 Phase I 1 country IOMX-0675; PEMBROLIZUMAB
OMX-0407 Phase I Study Ended

2024-514554-75-00 Phase I 3 countries OMX-0407

Showing 1–2 of 2 trials

← All sponsors A–Z